iRhythm HoldingsIRTC +1.31%75 FCF Yield % is 0.50 as of Jun. 25, 2026. GuruFocus rates IRTC with a GF Score™ of 75/100 and a GF Value™ of $162.87 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, iRhythm Holdings ranks better than 56.73% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
iRhythm Holdings FCF Yield % Related Terms
iRhythm Holdings FCF Yield % Historical Data
* Premium members only.
The historical data trend for iRhythm Holdings's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, iRhythm Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRhythm Holdings (IRTC) has a FCF Yield % of 0.50 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on iRhythm Holdings and its competitors. According to the industry distribution chart, iRhythm Holdings ranks #370 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 43.3%.
Is iRhythm Holdings' FCF Yield % too high?
iRhythm Holdings' current FCF Yield % is 0.50. Based on the distribution chart, iRhythm Holdings ranks #370 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, iRhythm Holdings has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' FCF Yield % compare to LIVN and HAE?
According to the Medical Devices & Instruments industry distribution chart, iRhythm Holdings ranks #370 out of 855 companies for FCF Yield %. This puts iRhythm Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on iRhythm Holdings and its competitors. iRhythm Holdings's current FCF Yield % is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Significantly Undervalued. The stock's GF Value™ is $162.87, compared to a current price of $113.93 — trading 30% below its estimated fair value. The current FCF Yield % is 0.50. iRhythm Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current FCF Yield % is 0.50 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $113.93 is trading 30% below its estimated GF Value™ of $162.87.
GuruFocus considers iRhythm Holdings to be Significantly Undervalued.
Key valuation signals for IRTC:
FCF Yield %: 0.50
GF Value™: $162.87 vs. price of $113.93 (30% below fair value)
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
75GF Score
Get the complete analysis for IRTC
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
